Clinical Trials

View onClinicalTrials.gov
Development Highlights:
1. Upstream RAS Targeting:
Designed to silence angiotensinogen (AGT) expression, reducing the precursor available for downstream angiotensin production and modulating the renin–angiotensin system (RAS) at its source.
2. RNAi-Based Antihypertensive Approach:
An investigational siRNA approach to blood pressure management that suppresses AGT synthesis, offering a distinct mechanism from therapies that inhibit downstream RAS enzymes or receptors.
3. Potential for Sustained Action:
Designed for sustained AGT suppression following subcutaneous administration, with the potential to support infrequent dosing for long-term hypertension management.
Thank You for Your Attention on Lepu Medical!
Email us with any questions or inquiries or use our contact data. We would be happy to answer your questions.
